Skip to main content
Log in

Desmopressin 25 and 50 μg oral lyophilisates (Noqdirna®; Nocdurna®) in nocturia due to nocturnal polyuria in adults: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Desmopressin 25 and 50 μg oral lyophilisates (hereafter Noqdirna®/Nocdurna®) are a new rapid-dispersing formulation of desmopressin that is indicated for the symptomatic treatment of nocturia due to nocturnal polyuria in adults of all ages. Noqdirna®/Nocdurna® is administered by placing the lyophilisate under the tongue until it dissolves, and provides greater absorption and bioavailability, as well as a more predictable pharmacokinetic profile, than standard oral desmopressin tablets, allowing lower desmopressin dosages to be used to achieve the same clinical outcomes. As responses to desmopressin differ by gender, dosages of Noqdirna®/Nocdurna® are also gender specific (25 μg in women and 50 μg in men). These dosages effectively reduced the number of nocturnal voids and increased the time to first nocturnal void in patients with nocturia, leading to improvements in sleep and nocturia-related quality of life. The use of desmopressin is associated with a risk of hyponatraemia; however, the risk is lower when lower dosages, such as 25 and 50 μg, are used. To further reduce the risk of hyponatraemia, gender-specific dosages of Noqdirna®/Nocdurna® should be used and serum sodium levels monitored appropriately before and during treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management: a systemic review and meta-analysis. Eur Urol. 2012;62(5):877–90.

    Article  PubMed  Google Scholar 

  2. Pesonen JS, Cartwright R, Mangera A, et al. Incidence and remission of nocturia: a systematic review and meta-analysis. Eur Urol. 2016;70(2):372–81.

    Article  PubMed  Google Scholar 

  3. Bosch JL, Weiss JP. The prevalence and causes of nocturia. J Urol. 2013;189(1 Suppl):S86–92.

    Article  PubMed  Google Scholar 

  4. Committee for Establishment of the Clinical Guidelines for Nocturia of the Neurogenic Bladder Society. Clinical guidelines for nocturia. Int J Urol. 2010;17(5):397–409.

    Article  CAS  Google Scholar 

  5. Oelke M, De Wachter S, Drake MJ, et al. A practical approach to the management of nocturia. Int J Clin Pract. 2017. https://doi.org/10.1111/ijcp.13027.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rao VN, Gopalakrishnan G, Saxena A, et al. Nocturia: symptom or a disease? J Assoc Physicians India. 2016;64(11):56–63.

    PubMed  Google Scholar 

  7. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodynam. 2002;21(2):179–83.

    Article  Google Scholar 

  8. Weiss JP, van Kerrebroeck PE, Klein BM, et al. Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol. 2011;186(4):1358–63.

    Article  PubMed  Google Scholar 

  9. Goessaert AS, Krott L, Hoebeke P, et al. Diagnosing the pathophysiologic mechanisms of nocturnal polyuria. Eur Urol. 2015;67(2):283–8.

    Article  PubMed  Google Scholar 

  10. Kallas HE, Chintanadilok J, Maruenda J, et al. Treatment of nocturia in the elderly. Drugs Aging. 1999;15(6):429–37.

    Article  PubMed  CAS  Google Scholar 

  11. Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med. 1991;229(2):131–4.

    Article  PubMed  CAS  Google Scholar 

  12. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.

    Article  PubMed  Google Scholar 

  13. Hester AG, Kretschmer A, Badlani G. Male incontinence: the etiology or basis of treatment. Eur Urol Focus. 2017. https://doi.org/10.1016/j.euf.2017.12.002 (Epub ahead of print).

    Article  PubMed  Google Scholar 

  14. Andersson F, Bing M, Holm-Larsen T, et al. Negative impact of nocturia on utility, productivity and health-related quality of life: results of a real world survey of patients in Europe and USA [abstract no. 588]. Eur Urol Suppl. 2014;13(1).

  15. Lee D, Nielsen SK, Kidd R, et al. Impact of nocturia on quality of life-mapping of SF-12 to utility values using clinical trial data [abstract no. PUK21]. Value Health. 2015;18(7):A511.

    Article  PubMed  CAS  Google Scholar 

  16. Nakagawa H, Niu K, Hozawa A, et al. Association between nocturia and mortality in a community-dwelling elderly population aged 70 years and over: results of a 3-year prospective cohort study in Japan [abstract no. 20]. J Urol. 2009;181(4 Suppl.):8.

    Article  Google Scholar 

  17. Trigg A, Andersson FL, Aldhouse NVJ, et al. Patients’ lived experiences of nocturia: a qualitative study of the evening, the night, and the next day. Patient. 2017;10(6):711–8.

    PubMed  PubMed Central  Google Scholar 

  18. Park HK, Kim HG. Current evaluation and treatment of nocturia. Korean J Urol. 2013;54(8):492–8.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Weiss JP, Juul KV, Wein AJ. Management of nocturia: the role of antidiuretic pharmacotherapy. Neurourol Urodyn. 2014;33(Suppl 1):S19–24.

    Article  PubMed  CAS  Google Scholar 

  20. Desmotabs (desmopressin) tablets 0.2 mg: UK summary of product characteristics. Drayton Hall: Ferring Pharmaceuticals Ltd.; 2012.

  21. DesmoMelt (desmopressin) 120 mcg and 240 mcg oral lyophilisate: UK summary of product characteristics. Drayton Hall: Ferring Pharmaceuticals Ltd.; 2011.

  22. Noqdirna (desmopressin) 25 and 50 microgram oral lyophilisate: summary of product characteristics. West Drayton: Ferring Pharmaceuticals Ltd; 2016.

  23. UK Electronic Medicines Compendium (eMC). Desmopressin. http://www.medicines.org.uk/emc/search. Accessed Jan 2018.

  24. De Guchtenaere A, Van Herzeele C, Raes A, et al. Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 2011;185(6):2308–13.

    Article  PubMed  CAS  Google Scholar 

  25. De Bruyne P, De Guchtenaere A, Van Herzeele C, et al. Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr. 2014;173(2):223–8.

    Article  PubMed  CAS  Google Scholar 

  26. Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDVAP) in hydrated normal subject. Clin Endocrinol (Oxf). 1998;48(2):235–41.

    Article  CAS  Google Scholar 

  27. Callreus T, Lundahl J, Hoglund P, et al. Changes in gastrointestinal motility influence the absorption of desmopressin. Eur J Clin Pharmacol. 1999;55(4):305–9.

    Article  PubMed  CAS  Google Scholar 

  28. Yamaguchi O, Nishizawa O, Juul KV, et al. Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial. BJU Int. 2013;111(3):474–84.

    Article  PubMed  CAS  Google Scholar 

  29. Juul KV, Klein BM, Sandstrom R, et al. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol. 2011;300(5):F1116–22.

    Article  PubMed  CAS  Google Scholar 

  30. Sender H, Weiss JP, Dmochowski RR, et al. Gender-specific dosing of desmopressin orally distintegrating tablet for nocturia [abstract no. MP-04.01]. Can Urol Assoc J. 2013;7(5–6 Suppl. 2):S60.

    Google Scholar 

  31. Sand PK, Dmochowski RR, Reddy J, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):958–64.

    Article  PubMed  CAS  Google Scholar 

  32. Weiss JP, Herschorn S, Albei CD, et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013;190(3):965–72.

    Article  PubMed  CAS  Google Scholar 

  33. Michelet R, Dossche L, De Bruyne P, et al. Effects of Food and pharmaceutical formulation on desmopressin pharmacokinetics in children. Clin Pharmacokinet. 2016;55(9):1159–70.

    Article  PubMed  CAS  Google Scholar 

  34. Weiss JP, Zinner NR, Klein BM, et al. Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double-blind, placebo-controlled trial. Neurourol Urodyn. 2012;31(4):441–7.

    Article  PubMed  CAS  Google Scholar 

  35. Bliwise DL, Holm-Larsen T, Goble S. Increases in duration of first uninterrupted sleep period are associated with improvements in PSQI-measured sleep quality. Sleep Med. 2014;15(10):1276–8.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Andersson FL, Anderson P, Juul KV, et al. Delay of optimal nocturia treatment is costly: results of a real world survey of patients in Europe and the USA [abstract no. PUK20]. Value Health. 2015;18(7):A511.

    PubMed  Google Scholar 

  37. Holm-Larsen T, Dijk D, Blemings A, et al. Kaplan-Meier survival analysis indicates improved undisturbed initial sleep in nocturia patients treated with desmopressin [abstract no. 0864]. Sleep. 2013;36(Suppl. 1):A296.

    Google Scholar 

  38. Juul KV, Jessen N, Bliwise DL, et al. Delaying time to first nocturnal void may have beneficial effects on reducing blood glucose levels. Endocrine. 2016;53(3):722–9.

    Article  PubMed  CAS  Google Scholar 

  39. Juul KV, Klein BM, Norgaard JP. Long-term durability of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn. 2013;32(4):363–70.

    Article  PubMed  CAS  Google Scholar 

  40. Rovner ES, Raymond K, Andruczyk E, et al. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms. 2017. https://doi.org/10.1111/luts.12169 (Epub ahead of print).

    Article  PubMed  Google Scholar 

  41. Teoh YJ, Chan C, Ng C, et al. Desmopressin oral lyophilisate lessens the burden of nocturia in the post-TURP men sooner they go asleep: an action unreachable by fluid restriction alone but attenuated by aging [abstract no. 626]. In: 15th Annual Meeting of the International Continence Society. 2017.

  42. Juul KV, Malmberg A, van der Meulen E, et al. Low-dose desmopressin combined with serum sodium monitoring can prevent clinically significant hyponatraemia in patients treated for nocturia. BJU Int. 2017;119(5):776–84.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: R.R. Dmochowski, Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville (TN), USA; M.G. Kirby, Faculty of Health and Human Sciences, University of Hertfordshire and The Prostate Centre, London, UK. During the peer review process, the manufacturer of Noqdirna®/Nocdurna® was also offered an opportunity to review this article for scientific accuracy. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Desmopressin 25 and 50 μg oral lyophilisates (Noqdirna®; Nocdurna®) in nocturia due to nocturnal polyuria in adults: a profile of its use. Drugs Ther Perspect 34, 105–115 (2018). https://doi.org/10.1007/s40267-018-0480-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0480-8

Navigation